Cytokinetics to Present at RBC Capital Markets Global Healthcare Conference
Event summary
- Cytokinetics will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026.
- The event will be webcast live and archived for 90 days on Cytokinetics' website.
- Cytokinetics recently reported positive topline results from the ACACIA-HCM Phase 3 trial for aficamten in non-obstructive HCM.
- The company is preparing to present full ACACIA-HCM results at an upcoming medical meeting and discuss them with the FDA.
The big picture
Cytokinetics' participation in the RBC conference comes at a pivotal time as it prepares to present full Phase 3 trial results for aficamten, potentially expanding its market opportunity beyond obstructive HCM. The company's focus on cardiac muscle dysfunction positions it in a growing segment of cardiovascular therapeutics, where innovative treatments for heart failure and hypertrophic cardiomyopathy are in high demand. The strategic significance of this conference appearance lies in its potential to influence investor perception ahead of key regulatory discussions.
What we're watching
- Regulatory Pathway
- Whether the full ACACIA-HCM results will support regulatory approval for aficamten in non-obstructive HCM.
- Pipeline Progress
- The pace of development for omecamtiv mecarbil and ulacamten in heart failure indications.
- Market Positioning
- How Cytokinetics positions itself against competitors in the cardiovascular therapy space.
Related topics